View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 14, 2017

Lung Therapeutics begins Phase Ia/b trial of LTI-01 for pleural effusions in Australia and New Zealand

US-based pharmaceutical company Lung Therapeutics has begun enrolment and dosing in a Phase Ia/b clinical trial of LTI-01 for the treatment of patients with loculated pleural effusions in Australia and New Zealand (NZ).

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

US-based pharmaceutical company Lung Therapeutics has begun enrolment and dosing in a Phase Ia/b clinical trial LTI-01 for the treatment of patients with loculated pleural effusions in Australia and New Zealand (NZ).

LTI-01 is an injectable, fibrinolytic drug that enhances scar removal around the lungs to improve fluid drainage, as well as reduce complications such as bleeding.

The Phase Ia/b trial is being conducted at three sites in each of the country and will evaluate the safety and maximum tolerable dose of LTI-01 in patients who have pneumonia-like symptoms, with a build-up of non-draining fluid around their lungs.

Lung Therapeutics chief executive officer Brian Windsor said: "We are pleased to have dosed the first patient in our Aus / NZ clinical trial with LTI-01.

"It is an exciting step forward in obtaining valuable safety and dosing data that will enable us to help CPE and empyema patients around the world. We are committed to giving these underserved patients better therapeutic options that are safer, simpler and less costly."

"We are pleased to have dosed the first patient in our Aus / NZ clinical trial with LTI-01."

LTI-01 was designed to treat empyema and complicated parapneumonic effusions (CPE), which are caused due to pneumonia and involve fibrinous scarring that prevents fluid drainage.

These complications may lead to pus or bacterial organisms in pleural fluids.

LTI-01 has secured orphan drug designation from the US Food & Drug Administration (FDA) in 2014 and from the European Union (EU) in 2015.

Lung Therapeutics primarily develops and commercialises safe and effective drugs for the non-surgical treatment of fibrosis in and around the lungs.


Image: Chest X-ray showing pleural effusion. Photo: courtesy of James Heilman/Wikipedia.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena